anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cigarette smoke is responsible for the majority of lung cancers and is the major cause of COPD, the fourth leading cause of death in the United States. Despite the well established causal role of cigarette smoking in lung cancer and COPD, only 10-20% of smokers actually develop these diseases. This suggests that there are genetic predisposing factors that place some individuals at greater risk. Our prior work shows that healthy smokers (cigarette smokers with normal history, physical exam, lung function tests and chest x-rays) and smokers with COPD have marked up and down regulation of greater than 200 genes in the small airway epithelium and alveolar macrophages. There is however, a varied response to smoking among individuals, with some individuals abnormally expressing far fewer genes. The focus of this study is to evaluate the hypothesis that the response of the lung cells to the stress of smoking is unique to each individual but is consistent over time. Furthermore, individuals that stop smoking will each have a unique response, but is constant over time for each individual. By defining the patterns of biologic response over time among smoking, ex-smoking and nonsmoking subjects, we will be able to identify common biologic pathways as potential targets for intervention.
Trabectedin 1.3 mg/m2 will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles. Trabectedin treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician.
PURPOSE: In a patient with elevated thyroid stimulating hormone (TSH, >50 µIU/ml) with sellar mass, it is crucial to differentiate isolated pituitary hyperplasia (IPH) from primary hypothyroidism coexisting with nonfunctioning pituitary adenoma (PHCNFPA) pre-operatively to avoid unwarranted surgery in the former condition. Here, we describe patients having pituitary mass/enlargement with markedly elevated TSH (>50 µIU/ml) and attempt to find the differentiating features between IPH and PHCNFPA.
METHODS: This is a retrospective study conducted at a tertiary care center. Case records of patients presenting between January 2020 and December 2022 with elevated TSH (>50 µIU/ml) for whom magnetic resonance imaging (MRI) of the sella was available were reviewed. Demographic details, symptomatology, clinical examination findings, thyroid function tests, data on pituitary hormonal excess and deficiencies, MRI findings, and details regarding levothyroxine supplementation were noted. Based on the final diagnosis, the patients were categorized into two groups: PHCNFPA and IPH.
RESULTS: Five and 11 patients were diagnosed with PHCNFPA and IPH, respectively. The median (IQR) age at presentation of patients with PHCNFPA was significantly higher than that of IPH patients [37 (28-60.5) vs. 21 (10-21.5) years, p: 0.002]. A longer duration of hypothyroid symptoms was noted in the IPH group whereas visual field defects and corticotropin deficiency were more frequent and the pituitary lesion size was greater in PHCNFPA. Thyroid function tests were not different between the two groups. The pituitary enlargement in IPH was initially an increase in pituitary height that progressed to symmetrical nipple-, dome- or tent-shaped enlargement. Besides this characteristic enlargement pattern, isointense appearance on T1-weighted and T2-weighted images, homogeneous contrast enhancement, and prompt regression of pituitary lesion with levothyroxine replacement were characteristic of IPH whereas heterogeneous enhancement, cystic/hemorrhagic change, and ≥Knosp III invasion were characteristic of PHCNFPA. Peripheral rim enhancement and Knosp I-II parasellar extension were not uncommon in patients with IPH and did not distinguish it from PHCNFPA.
CONCLUSIONS: The present study reports the radiological evolution of IPH and a unique series of PHCNFPA along with the distinguishing characteristics between them.
The invention relates to a method for detecting medicine composition for warming the spleen and tonifying the kidney and releasing turbidity and eliminating stasis. The method includes content determination and identification methods or detection of limited quantity of aconitine. In the content determination method, the high performance liquid chromatography is adopted. The detection method of the invention also includes identification of ginseng, liquorice and rhizoma zingiberis and detection of aconitine. The detection method of the invention features good specificity, high stability, good repeatability and high precision, thus being more suitable for industrialized production and ensuring safe, effective and reliable clinical medication. In addition, the preparation prepared by the alcohol extraction method has better effect.
Ascites is the pathological accumulation of fluid within the peritoneal cavity. It often occurs as results of liver cirrhosis, malignant neoplasia, tuberculous infection, cardiac insufficiency, renal diseases, etc. Determining the etiology is an essential step in the management of patients with new-onset ascites. Abdominal paracentesis with appropriate ascitic fluid analysis is probably the most cost-effective method of determining the cause of ascites. We performed a literature search of PubMed and identified articles published in the field of ascites, to evaluate diagnostic values of various parameters in defining the etiologies of ascites and then provides diagnostic algorithm for patients with new-onset ascites. In patients with ascites, the constituent ratio of underlying etiology varies between developed and developing countries. It is a challenge to define the etiologies of ascites in developing countries. Routine ascitic fluid analysis should include the serum ascites albumin gradient (SAAG), total protein concentration, cell count and differential. Optional ascitic fluid analysis includes cholesterol, fluid culture, cytology, tumor markers, lactate dehydrogenase, adenosine deaminase (ADA), triglyceride, amylase, glucose, brain natriuretic peptide (BNP), etc. Our review evaluated diagnostic values of the above parameters in defining the etiologies of ascites. Diagnostic algorithm established in this review would provide a practical and convenient diagnostic strategy for clinicians in diagnosing patients with new-onset ascites.
Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen  Candidaalbicans,  the major cause of hospital-acquired fungal infections, is found at similar sites. Here it is demonstrated that DC-SIGN is able to bind  Candida albicans  both in DC-SIGN transfected cell lines and in human monocyte derived DC. Moreover, in immature DC, DC-SIGN is able to internalize  Candida  in specific DC-SIGN enriched vesicles, distinct from those containing the mannose receptor (MR; CD206), which is another  Candida  receptor on DC. Together, these results demonstrate that  C. albicans  has two major receptors on human monocyte derived DC, these receptors being DC-SIGN and MR. Targeting of DC-SIGN offers novel opportunities to combat chronic forms of candidiasis.
Inflammatory bowel disease (IBD), mainly comprising ulcerative colitis and Crohn's disease, is a group of gradually progressive diseases bringing significant mental anguish and imposes serious economic burdens. Interplay of genetic, environmental, and immunological factors have been implicated in its pathogenesis. Nutrients, as crucial environmental determinants, mainly encompassing carbohydrates, fats, proteins, and micronutrients, are closely related to the pathogenesis and development of IBD. Nutrition is essential for maintaining the dynamic balance of intestinal eco-environments to ensure intestinal barrier and immune homeostasis, while this balance can be disrupted easily by maladjusted nutrition. Research has firmly established that nutrition has the potential to shape the composition and function of gut microbiota to affect the disease course. Unhealthy diet and eating disorders lead to gut microbiota dysbiosis and further destroy the function of intestinal barrier such as the disruption of membrane integrity and increased permeability, thereby triggering intestinal inflammation. Notably, appropriate nutritional interventions, such as the Mediterranean diet, can positively modulate intestinal microecology, which may provide a promising strategy for future IBD prevention. In this review, we provide insights into the interplay between nutrition and gut microbiota and its effects on IBD and present some previously overlooked lines of evidence regarding the role of derived metabolites in IBD processes, such as trimethylamine N-oxide and imidazole propionate. Furthermore, we provide some insights into reducing the risk of onset and exacerbation of IBD by modifying nutrition and discuss several outstanding challenges and opportunities for future study.
A 25 fold increase in the risk of going blind on diagnosis of diabetes is one of the most daunting threats that patients face. People using insulin are particularly challenged because they are unable accurately to draw up their dose of drug. Most cases of vision impairment in diabetes are due to macular oedema that persists or recurs after laser treatment. There are now a number of uncontrolled, anecdotal reports that intravitreal triamcinolone (IVTA) is highly effective for the treatment of diabetic macular edema which is refractory to conventional laser treatment. We commenced the first placebo-controlled, double masked clinical trial of IVTA for refractory macular oedema in 2002. The 3 month results from this study provide the first scientific proof of principle that IVTA reduces macular thickness and improves vision. The two year results will be available in March 2005, but confidential interim analysis of efficacy data in September 2004 suggested that the beneficial effect of triamcinolone treatment persisted. Thus it appears that treatment with IVTA may be the most significant development for the prevention of blindness in people with diabetes since the introduction of laser treatment. It would also be a highly cost-effective intervention that could be administered by general ophthalmologists. The treatment cannot be recommended for routine use, however, until its long term efficacy and safety have been established. Since we already have a well studied group of patients who have received treatment for 2 years, we are in a unique position to extend the study in order to provide the long-term (5-year) safety and efficacy data that does not appear to be forthcoming from any other source. The completion of this study will have a direct and immediate effect on the risk of blindness in people with diabetes by allowing doctors to predict more accurately the long term effects of this promising new treatment.
The present disclosure provides an eyeliner product and a method thereof. The eyeliner product includes components as follows: foundation makeup liquid, acrylic acid octyl acrylamide copolymer or propylene ester octyl acrylamide copolymer, tackifier, vegetable gum, and surface modifier. The eyeliner product is provided by weight. The acrylic acid octyl acrylamide copolymer or the propylene ester octyl acrylamide copolymer is provided in an amount ranging from 10-11 parts. The tackifier is provided in an amount ranging from 1-3 parts. The vegetable gum is provided in an amount ranging from 6-12 parts. The surface modifier is provided in an amount ranging from 0.1-2 parts. And the vegetable gum is starch glue.
The present invention relates to a combined preparation of sodium aminosalicylate and trimethoprim, which is a compound preparation made by mixing two common medicines according to a certain proportion, wherein one medicine is a conventional antituberculotic medicine and the other medicine is a traditional medicine for the new application of treating tuberculosis. The sodium aminosalicylate and the trimethoprim are used as raw materials and are mixed according to the dose proportion from 5:0.25 to 0.5. Compound sodium aminosalicylate is made by the method of producing sodium aminosalicylate tablets. Thus, the synthesis of the tubercle bacillus folic acid is blocked in two ways. The trimethoprim has stable chemical property and can be dissolved in water in a very-low amount which is greatly differed from the water solubility of the sodium aminosalicylate. Thus, the powder mix of the trimethoprim and the sodium aminosalicylate does not have chemical change. The present invention is the new antitubercular medicine which is the combined preparation providing medicine selecting chances for medical-resistant tuberculous treatment, reducing patients' medication dosage and medication times, providing convenience for patients, increasing treating effects, delaying medical resistance and reducing toxic and side reaction.
In the AI group, except for the original videos, there is additional information presented to endoscopists:（1）the virtual stomach model monitoring;（2）time;（3）scoring. Endoscopists will complete EGD examination without blind spots.
The prophylactic form is in the form of soft seamless gelatine capsules and shall be used as an additive to the daily diet. It is recommended in case of higher cholesterol level in the blood and in cardiac infarction risks, as a powerful antioxidant against stress, chronic and viral diseases, in risk of cataract formation, as well as for the normal development of the sexual glands of the foetus in pregnancy and in reduced spermatogenesis. The contents of the soft gelatine capsules is a homogenous mixture of natural vitamin E (d-alpha-tocoferol) - from 3.60 to 4.40 wt. %, and oil from wheat germ (cold-pressed) from 86.40 to 105.6 wt. %. 3 claims
BACKGROUND: Ischaemia-evoked neuroinflammation is a critical pathogenic event following ischaemic stroke. Gasdermin D (GSDMD)-associated pyroptosis represents a type of inflammation-associated programmed cell death, which can exacerbate neuroinflammatory responses and brain damage. Stimulator of interferon genes (STING) was recently described as a vital innate immune adaptor protein associated with neuroinflammation. Nevertheless, the regulatory effects of STING on microglial pyroptosis post-stroke have not been well elaborated.
METHODS: STING-knockout and wild-type (WT) mice were subjected to middle cerebral artery occlusion (MCAO). STING small interfering RNA (siRNA) was transfected into BV2 cells before oxygen-glucose deprivation/reoxygenation (OGD/R). STING-overexpressing adeno-associated virus (AAV) and NOD-like receptor family pyrin domain containing 3 (NLRP3) siRNA were administered by stereotaxic injection. 2,3,5-Triphenyl tetrazolium chloride (TTC) staining, TdT-mediated dUTP nick end labeling (TUNEL) staining, Fluoro-Jade C (FJC) staining, neurobehavioural tests, immunohistochemistry, cytokine antibody array assay, transmission electron microscopy, immunoblot, Enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR) were carried out. Co-immunoprecipitation assays were used to investigate the interplay between STING and NLRP3.
RESULTS: STING expression was increased after MCAO and mainly detected on microglia. STING deletion alleviated brain infarction, neuronal damage and neurobehavioural impairment in mice subjected to MCAO. STING knockout suppressed microglial activation and the secretion of inflammatory chemokines, accompanied by mitigation of microglial pyroptosis. Specific upregulation of microglial STING by AAV-F4/80-STING aggravated brain injury and microglial pyroptosis. Mechanistically, co-immunoprecipitation showed that STING bound to NLRP3 in microglia. Supplementation of NLRP3 siRNA reversed AAV-F4/80-STING-induced deterioration of microglial pyroptosis.
CONCLUSIONS: The current findings indicate that STING modulates NLRP3-mediated microglial pyroptosis following MCAO. STING may serve as a therapeutic target in neuroinflammation induced by cerebral ischaemic/reperfusion (I/R) injury.
The invention discloses a high-molecular material containing cholic acid and a drug-loaded nanoparticle modified by the same. The material has a structural formula as represented by formula III, and n in the formula is equal to 25 to 40. Monomers of the material are obtained by reacting hydroxy groups at C3 position of cholic acid methylester with 4-vinylbenzyl chloride and are initiated by an initiator so as to obtain a polymer precursor; ester groups at C24 position of the polymer precursor are hydrolyzed and turn into carboxyl groups so as to obtain the material in the invention. The material has amphipathy and is capable of assembling and of modifying the surface of the nanoparticles in the process of preparing the nanoparticles by using the method of emulsification-solvent evaporation. The molecular structure of cholic acid in the material can specifically bind to bile acid transporters on the surface of parenchymal hepatic cells; under the mediation of the bile acid transporters, the nanoparticles are absorbed by the parenchymal hepatic cells, and therefore, a drug is targetedly delivered to the parenchymal hepatic cells. Thus, the material provided in the invention can be used as an ideal surface modification material for development of a liver-targeting nanometer drug loading system.
Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
A method for analysis in medical diagnostics in accordance with the present invention can comprise the steps of collecting measurement data, analysing analysis data corresponding to at least a portion of the measurement data and thereby generating an analysis result, and/or storing the measurement data and/or analysis data and/or analysis result in a data storage system. The step of storing the measurement data and/or analysis data and/or analysis result in the data storage system can comprise transmitting a request for storing the measurement data and/or analysis data and/or analysis result to an interface module, and/or in response, the interface module prompting the measurement and/or analysis data and/or analysis result data to be stored in the data storage system. The invention is directed to a system for analysis in medical diagnostics, wherein the system can comprise a main module, at least one measurement device configured to provide measurement data on a sample and/or subject, at least one analysis module configured to analyse analysis data and provide an analysis result, a data storage system configured to store and provide data, and/or an interface module. The system can additionally or alternatively comprise a plurality of software- based toolsets in a data storage system wherein the system is configured to transfer one or more toolset(s) to a user in response to a query transfer. The data storage system can be configured to store the measurement data and/or analysis data and/or analysis result. The system and method can be configured for spectral analysis in medical diagnostics, wherein the medical diagnostics can be metabolite diagnostics.
FIELD: medicine, pharmacy. SUBSTANCE: method involves mixing the defatted solution of α-fetoprotein in physiological solution with antitumor drug and arachidonic acid. Mixture is kept at 4 ± 0.5 C, filtered and frozen. α-Fetoprotein is isolated preferably from biological material by 2-stage affinity chromatography on immunosorbents. EFFECT: improved method of preparing. 6 cl, 1 tbl
1. Technical Result Increase in treatment efficiency and reduction of side effects.  2. Essence An insect nonsteroidal pheromone, or its derivative, or its synthetic analog that is unsaturated aliphatic alcohol, aldehyde or ester, with linear, aliphatic, carbon chain length 10-21 carbon atoms is used as antiglucocorticoid means.  3. Field of Application Medicine, therapy.
The invention relates to a traditional Chinese medicine preparation for the treatment of cerebrovascular diseases and a preparation method. The preparation is prepared by a formula A: membranous milkvetch root, angelicae sinensis radix, red paeony root, Tibet safflower, danshen root, Szechuan lovage rhizome, earthworm and largeleaf gentian root; and a formula B: 27 traditional Chinese medicines of membranous milkvetch root, safflower, sanchi, leech, Chinese caterpillar fungus and others. Then, the processing is carried out according to the process flow, and the micro-powder processing of the traditional Chinese medicines is carried out by adopting the modern high-tech micro-powder technology. The preparation form is a capsule, which can also be developed into a tablet. The preparation has marked effect in treating cerebrovascular diseases and the complications which are caused by the cerebrovascular diseases. The total effective rate of the drug is 80 percent by clinical verification. The traditional Chinese medicine preparation has the characteristics of short course of treatment, significant efficacy and no obvious toxicity or side effects, thus being applicable to the large-scale development of domestic and foreign pharmaceutical companies.
This side-by-side split body, blinded, randomized single-center study is comparing two different 810 nm diode laser technologies for the purpose of permanent hair reduction to determine the effectiveness and subject's tolerance for hair reduction. Twenty volunteers will be enrolled into this study. Subjects will receive a total of 5 treatments of either axilla or lower legs. 10 patients will have both axilla treated while the other 10 subjects will have the lower legs treated. Placement to the axilla treatment group vs. the lower leg treatment group is random.

Treatment areas will be randomized to receive Soprano SHR treatment or Light Sheer/Duet treatment. One extremity (example: right axilla) will receive Soprano SHR treatment and the contra-lateral extremity (example: left axilla) will receive Duet treatment. The treatments will occur every 6 - 8 weeks and then there will be follow up visits at 1 month, 6 months, and 12 months after the last treatment.
Epithelial ovarian cancer is the most lethal female reproductive malignancy, mainly because 80% of tumors have metastasized beyond the ovary at the time of diagnosis. Screening efforts aimed at improved identification of early stage disease have been largely unsuccessful, because of ovarian cancer's propensity for early spread. Our hypothesis is that this obstacle can be circumvented by identifying biomarkers for the precancerous stage of this disease. Since this pre-cancerous stage is currently undetectable, we instead propose to look for biomarkers in women at very high risk for developing ovarian cancer due to genetic mutations. We hypothesize that identification of markers for genetic predisposition to ovarian cancer will also be informative for detection of biological changes that over time lead to sporadic cancers. Given their increasingly recognized role in states of normal and abnormal growth and differentiation, we hypothesize that short non-coding RNAs (sncRNAs) hold significant promise as biomarkers of ovarian cancer predisposition. We will test these hypotheses in two aims. First, we will identify biomarkers for hereditary ovarian cancer risk by comparing serum-derived sncRNAs in women with and without hereditary risk for ovarian cancer. In the second aim we will define serum-derived sncRNAs correlates of ovarian cancer disease status. We will compare sera from ovarian cancer patients at times of highest and lowest disease burden to those of control, cancer-free subjects. Each aim will provide independent, novel, and important information for future investigations. The sncRNAs found to be differentially expressed in both aims will be prioritized for future validation in women under clinical surveillance for hereditary risk of ovarian cancer.